• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在突破盲态之前的非计划性调整。

Unplanned adaptations before breaking the blind.

机构信息

European Medicines Agency, 7 Westferry Circus, E14 4HB London, UK.

出版信息

Stat Med. 2012 Dec 30;31(30):4146-53. doi: 10.1002/sim.5361. Epub 2012 Jun 27.

DOI:10.1002/sim.5361
PMID:22736397
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3576479/
Abstract

Occasionally, things go so wrong in a clinical trial that a change must be made. For example, the originally planned primary outcome may be measured completely unreliably. Is there any recourse? One may still be able to salvage the trial using a permutation test if a change is made before breaking the treatment blind. The solution is not a panacea; we discuss the limitations and legitimate grounds for criticism. Still, when it is needed, the procedure is preferable to rigid adherence to a design that makes no sense. Published 2012. This article is a US Government work and is in the public domain in the USA.

摘要

偶尔,临床试验中会出现非常严重的问题,以至于必须进行更改。例如,最初计划的主要结果可能完全不可靠。有什么补救措施吗?如果在打破治疗盲法之前进行更改,仍然可以使用排列检验来挽救试验。该解决方案并非万无一失;我们讨论了局限性和批评的合理依据。尽管如此,在需要时,该程序比坚持毫无意义的设计更为可取。2012 年出版。本文是美国政府的一项工作,在美国属于公有领域。

相似文献

1
Unplanned adaptations before breaking the blind.在突破盲态之前的非计划性调整。
Stat Med. 2012 Dec 30;31(30):4146-53. doi: 10.1002/sim.5361. Epub 2012 Jun 27.
2
Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial.静脉注射免疫球蛋白治疗复发缓解型多发性硬化症:一项剂量探索试验。
Neurology. 2009 Jun 16;72(24):2134; author reply 2134-5. doi: 10.1212/01.wnl.0000349656.65459.5f.
3
Blinded sample size reestimation with count data: methods and applications in multiple sclerosis.盲法样本量重估与计数数据:多发性硬化中的方法与应用。
Stat Med. 2010 May 10;29(10):1145-56. doi: 10.1002/sim.3861.
4
Method of balanced adjustment in testing co-primary endpoints.联合主要终点检测中的平衡调整方法。
Stat Med. 2010 Aug 30;29(19):2055-66. doi: 10.1002/sim.3950.
5
What's new in trial design: propensity scores, equivalence, and non-inferiority.试验设计的新进展:倾向评分、等效性和非劣效性。
J Extra Corpor Technol. 2009 Dec;41(4):P6-10.
6
On the Comparison of Methods in Analyzing Bounded Outcome Score Data.《有界结局评分数据分析方法比较》
AAPS J. 2019 Aug 26;21(6):102. doi: 10.1208/s12248-019-0370-6.
7
The clinician as investigator: participating in clinical trials in the practice setting: Appendix 1: fundamentals of study design.临床医生作为研究者:在临床实践中参与临床试验:附录1:研究设计基础
Circulation. 2004 Jun 1;109(21):e302-4. doi: 10.1161/01.CIR.0000128807.57602.61.
8
An alternative method for estimating efficacy of the AN1792 vaccine for Alzheimer disease.一种评估AN1792阿尔茨海默病疫苗疗效的替代方法。
Neurology. 2008 Aug 26;71(9):697; author reply 697-8. doi: 10.1212/01.wnl.0000325484.81127.15.
9
You get what you measure: evaluating endpoints in MS clinical trials.你衡量什么,就会得到什么:评估多发性硬化症临床试验中的终点指标。
Neurology. 2008 Aug 26;71(9):620-1. doi: 10.1212/01.wnl.0000324619.41610.b8. Epub 2008 Aug 6.
10
Cut-points for the measurement of pain: the choice depends on what you want to study.疼痛测量的切点:选择取决于你想要研究的内容。
Pain. 2010 May;149(2):163-164. doi: 10.1016/j.pain.2010.03.013. Epub 2010 Mar 26.

引用本文的文献

1
A Preplanned Multi-Stage Platform Trial for Discovering Multiple Superior Treatments With Control of FWER and Power.一项预先计划的多阶段平台试验,用于发现多种具有控制家族性错误率(FWER)和检验功效的优势治疗方法。
Biom J. 2025 Feb;67(1):e70025. doi: 10.1002/bimj.70025.
2
Statistical Issues and Recommendations for Clinical Trials Conducted During the COVID-19 Pandemic.
Stat Biopharm Res. 2020 Jul 6;12(4):399-411. doi: 10.1080/19466315.2020.1779122.
3
The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.适应性设计 CONSORT 扩展(ACE)声明:一份带有解释和说明指南的清单,用于报告使用适应性设计的随机试验。
BMJ. 2020 Jun 17;369:m115. doi: 10.1136/bmj.m115.
4
The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.适应性设计 CONSORT 扩展(ACE)声明:一份带有解释和说明指南的清单,用于报告使用适应性设计的随机试验。
Trials. 2020 Jun 17;21(1):528. doi: 10.1186/s13063-020-04334-x.
5
Adaptive designs in clinical trials: from scientific advice to marketing authorisation to the European Medicine Agency.临床试验中的适应性设计:从向欧洲药品管理局寻求科学建议到获得上市许可
Trials. 2018 Nov 20;19(1):642. doi: 10.1186/s13063-018-3012-x.
6
Estimation after blinded sample size reassessment.盲法样本量再评估后的估计。
Stat Methods Med Res. 2018 Jun;27(6):1830-1846. doi: 10.1177/0962280216670424. Epub 2016 Oct 2.
7
Maximum type I error rate inflation from sample size reassessment when investigators are blind to treatment labels.当研究人员对治疗标签不知情时,样本量重新评估导致的最大I型错误率膨胀。
Stat Med. 2016 May 30;35(12):1972-84. doi: 10.1002/sim.6848. Epub 2015 Dec 23.
8
Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls.二十五年的验证性适应性设计:机遇与陷阱。
Stat Med. 2016 Feb 10;35(3):325-47. doi: 10.1002/sim.6472. Epub 2015 Mar 16.
9
Connections between permutation and t-tests: relevance to adaptive methods.排列检验与t检验之间的联系:与自适应方法的相关性。
Stat Med. 2014 Nov 30;33(27):4734-42. doi: 10.1002/sim.6288. Epub 2014 Aug 25.

本文引用的文献

1
A randomized study of alglucosidase alfa in late-onset Pompe's disease.一项针对晚发性庞贝病的阿糖苷酶 α 的随机研究。
N Engl J Med. 2010 Apr 15;362(15):1396-406. doi: 10.1056/NEJMoa0909859.
2
Tests for differentiation in gene expression using a data-driven order or weights for hypotheses.
Biom J. 2005 Aug;47(4):554-62. doi: 10.1002/bimj.200410118.
3
A method to estimate the variance of an endpoint from an on-going blinded trial.一种从正在进行的盲法试验中估计终点指标方差的方法。
Stat Med. 2005 Jun 30;24(12):1807-14. doi: 10.1002/sim.2070.
4
A general statistical principle for changing a design any time during the course of a trial.在试验过程中的任何时候更改设计的一般统计原则。
Stat Med. 2004 Aug 30;23(16):2497-508. doi: 10.1002/sim.1852.
5
Simple procedures for blinded sample size adjustment that do not affect the type I error rate.不影响I型错误率的盲法样本量调整的简单程序。
Stat Med. 2003 Dec 15;22(23):3571-81. doi: 10.1002/sim.1585.
6
A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema.一项比较肺减容手术与药物治疗重度肺气肿的随机试验。
N Engl J Med. 2003 May 22;348(21):2059-73. doi: 10.1056/NEJMoa030287. Epub 2003 May 20.
7
Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial.激素替代疗法和抗氧化维生素补充剂对绝经后女性冠状动脉粥样硬化的影响:一项随机对照试验。
JAMA. 2002 Nov 20;288(19):2432-40. doi: 10.1001/jama.288.19.2432.
8
Patients at high risk of death after lung-volume-reduction surgery.肺减容手术后死亡风险高的患者。
N Engl J Med. 2001 Oct 11;345(15):1075-83. doi: 10.1056/NEJMoa11798.
9
On model prespecification in confirmatory randomized studies.关于验证性随机研究中的模型预设
Stat Med. 1999 Apr 15;18(7):771-85. doi: 10.1002/(sici)1097-0258(19990415)18:7<771::aid-sim80>3.0.co;2-e.
10
A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group.一项关于饮食模式对血压影响的临床试验。DASH 协作研究小组。
N Engl J Med. 1997 Apr 17;336(16):1117-24. doi: 10.1056/NEJM199704173361601.